Biogen Inc.'s Form 4 filing

Sangamo Therapeutics, Inc (SGMOQ) · filed Aug 31, 2022

Accession no.: 0000899243-22-030136
Filed: Aug 31, 2022, 7:03 PM ET
Trade date: Aug 29-30, 2022
Filing delay: 2 days
Rule 10b5-1 plan: Not on the form (before 2023)

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $2.66M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Biogen Inc.CIK 0000875045	10% Owner
Biogen MA Inc.CIK 0001810387	10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Aug 29, 2022	Common Stock	SSaleDisposed	−400,000	$5.33^F1	−$2,130,720	23,752,466	Indirect
Aug 30, 2022	Common Stock	SSaleDisposed	−100,000	$5.27^F3	−$526,520	23,652,466	Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.205 to $5.475, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.1235 to $5.49, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)